Targets › CPA2
1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Jul 2030.
Carboxypeptidase that catalyzes the release of a C-terminal amino acid, with a preference for large aromatic C-terminal residues. (UniProt, P48052)
Open in Phaseline: the race on CPA2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Northwell Health | Post transplant cyclophosphamide Alkylating agent; prodrug requiring hepatic metabolism to active phosphoramide mustard tha | CPA1, CPA2 | Phase 1 | GVHD - Graft-Versus-Host Disease | Jul 2030 |
GVHD - Graft-Versus-Host Disease (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.